|
HIV+ person's risk of contracting the disease and level of disease severity, compared with noninfected people |
Cost* |
Frequency |
Serologic efficacy in HIV+ persons |
Clinical efficacy in HIV+ persons |
ACC authors' conclusions |
|
| Pneumococcal vaccine |
Markedly increased |
$10.60 |
Once; some recommend repeat after 6 yrs |
Correlates with CD4 cell count |
Unknown |
Offered routinely |
| Influenza vaccine |
Unclear whether higher incidence of disease or worse outcome |
$4.37 |
Annually |
Correlates with CD4 cell count |
Unknown |
Considered but not always recommended for people with low CD4 cell counts |
| Hepatitis vaccine |
Severity is lower but risk of chronic carriage higher |
$156.75 for series |
3-dose series IM, one time only; repeat if no response |
Correlates with CD4 cell count |
Unknown |
Offered routinely to susceptible individuals engaging in high-risk behavior |
| H. influenza vaccine |
Moderately increased risk and severity |
$62.56 |
Once |
Usually correlates with CD4 cell count |
Unknown |
Considered least important intervention of these four vaccines and not routinely recommended when CD4 cell count is low |
